Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (Q3)Sep 30, 2025 | (Q2)Jun 30, 2025 | (Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | 1.60%1.14M | 59.97%1.27M | -36.66%959K | 858.89%5.02M | 35.14%1.6M | 56.49%1.12M | 164.34%792K | 1,028.83%1.51M | -60.85%523K | 5.43%1.18M |
| Net income from continuing operations | 29.06%-2.37M | -32.50%-4.26M | 0.31%-3.54M | -0.65%-13.27M | 10.87%-3.17M | -8.13%-3.34M | 19.46%-3.21M | -39.15%-3.55M | -13.95%-13.19M | -48.00%-3.56M |
| Operating gains losses | -5,395.83%-1.32M | -233.33%-20K | -190.00%-9K | -2,671.43%-180K | -835.00%-147K | 41.46%-24K | 66.67%-6K | -73.68%10K | -97.24%7K | -75.90%20K |
| Depreciation and amortization | -4.58%2.29M | -4.75%2.31M | -3.18%2.34M | -7.23%9.61M | -17.20%2.36M | -5.80%2.4M | -2.02%2.42M | -2.42%2.42M | 2.67%10.35M | 12.85%2.85M |
| Asset impairment expenditure | ---- | ---- | ---- | ---- | ---- | -34.55%72K | -16.16%83K | -20.00%48K | ---- | ---- |
| Remuneration paid in stock | -25.35%159K | 8.66%251K | 24.59%228K | 46.27%863K | 3.96%236K | 10.36%213K | 821.88%231K | -9.41%183K | -14.24%590K | 97.39%227K |
| Other non cashItems | 51.20%2.21M | 72.35%2.36M | 32.83%1.94M | 64.27%6.06M | 93.11%1.77M | 79.90%1.46M | -1.44%1.37M | 155.15%1.46M | 3.42%3.69M | -33.89%915K |
| Change In working capital | -58.68%169K | 7,987.50%631K | -100.81%-8K | 309.15%1.94M | -44.83%555K | 127.22%409K | 99.30%-8K | 202.17%987K | 55.91%-929K | 275.57%1.01M |
| -Change in receivables | 987.50%87K | 183.72%72K | -72.00%84K | 1,587.50%238K | -90.80%16K | 105.23%8K | -530.00%-86K | 626.32%300K | 55.56%-16K | -79.95%174K |
| -Change in prepaid assets | 7,633.33%226K | --0 | -51.42%-427K | 99.33%297K | 85.63%297K | -101.00%-3K | 359.09%285K | -39.60%-282K | 118.60%149K | 138.65%160K |
| -Change in payables and accrued expense | -121.65%-97K | 295.88%476K | -68.26%293K | 221.50%1.36M | -64.33%234K | 8,860.00%448K | 79.00%-243K | 247.68%923K | 2.10%-1.12M | 161.95%656K |
| -Change in other working capital | -6.82%-47K | 130.56%83K | -8.70%42K | -22.03%46K | -50.00%8K | -262.96%-44K | -63.27%36K | 156.10%46K | 147.20%59K | -50.00%16K |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | 1.60%1.14M | 59.97%1.27M | -36.66%959K | 858.89%5.02M | 35.14%1.6M | 56.49%1.12M | 164.34%792K | 1,028.83%1.51M | -60.85%523K | 5.43%1.18M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 221.32%865K | -111.71%-1.54M | 40.38%-753K | 29.95%-3.52M | 41.20%-815K | -17.27%-713K | -59.56%-726K | 50.89%-1.26M | -126.67%-5.02M | 18.33%-1.39M |
| Net PPE purchase and sale | 142.23%345K | -71.59%-1.21M | 29.90%-776K | 37.92%-3.33M | 35.04%-697K | 16.63%-817K | 51.68%-704K | 40.03%-1.11M | 13.78%-5.36M | 30.10%-1.07M |
| Net intangibles purchas and sale | 18.18%-9K | 85.00%-6K | 89.29%-15K | 65.26%-206K | 90.00%-15K | 92.62%-11K | 69.23%-40K | 14.63%-140K | ---593K | ---150K |
| Net investment purchase and sale | --234K | ---- | ---- | -99.01%9K | --9K | --0 | --0 | ---- | 178.58%910K | --0 |
| Net other investing changes | 156.52%295K | -1,894.44%-323K | 337.50%38K | -72.22%5K | 31.29%-112K | -77.93%115K | -91.89%18K | 97.15%-16K | -99.93%18K | -13.99%-163K |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | 221.32%865K | -111.71%-1.54M | 40.38%-753K | 29.95%-3.52M | 41.20%-815K | -17.27%-713K | -59.56%-726K | 50.89%-1.26M | -126.67%-5.02M | 18.33%-1.39M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | -239.21%-2.38M | -89.64%84K | -17.68%-2.54M | -170.50%-1.9M | -231.60%-2.26M | 182.14%1.71M | -82.85%811K | -28.43%-2.16M | 113.90%2.69M | -66.35%1.72M |
| Net issuance payments of debt | -239.21%-2.38M | -72.63%222K | -17.68%-2.54M | -186.81%-2.04M | -274.38%-2.4M | 182.14%1.71M | -82.85%811K | -28.43%-2.16M | 111.96%2.35M | -71.15%1.38M |
| Cash dividends paid | --0 | --0 | ---- | ---- | ---- | --0 | --0 | ---- | ---- | ---- |
| Proceeds from stock option exercised by employees | ---- | ---- | ---- | -96.14%13K | ---- | ---- | ---- | ---- | 53.18%337K | ---- |
| Interest paid (cash flow from financing activities) | --0 | ---138K | ---- | ---- | ---- | --0 | --0 | ---- | ---- | ---- |
| Net other financing activities | ---- | ---- | ---- | --133K | ---- | ---- | ---- | ---- | ---- | ---- |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | -239.21%-2.38M | -89.64%84K | -17.68%-2.54M | -170.50%-1.9M | -231.60%-2.26M | 182.14%1.71M | -82.85%811K | -28.43%-2.16M | 113.90%2.69M | -66.35%1.72M |
| Net cash flow | ||||||||||
| Beginning cash position | -49.28%1.7M | -24.40%1.87M | -4.45%4.19M | -29.21%4.4M | 88.63%5.49M | -30.74%3.35M | 38.83%2.47M | -29.57%4.38M | 13.48%6.22M | 63.39%2.91M |
| Current changes in cash | -117.49%-370K | -121.21%-186K | -22.37%-2.33M | 78.07%-397K | -197.29%-1.47M | 207.47%2.12M | -71.17%877K | 56.85%-1.9M | -320.19%-1.81M | -66.54%1.51M |
| Effect of exchange rate changes | -233.33%-32K | 233.33%20K | 190.00%9K | 2,671.43%180K | 835.00%147K | -41.46%24K | -66.67%6K | 66.67%-10K | 91.57%-7K | ---20K |
| End cash Position | -76.37%1.3M | -49.28%1.7M | -24.40%1.87M | -4.93%4.19M | -4.93%4.19M | 88.63%5.49M | -30.74%3.35M | 38.83%2.47M | -29.21%4.4M | -29.21%4.4M |
| Free cash from | -57.48%125K | 10.42%53K | -37.08%168K | 127.35%1.48M | 2,376.92%888K | 171.36%294K | 101.70%48K | 112.29%267K | -11.28%-5.43M | 90.53%-39K |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | Unqualified Opinion | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.